How to verify tesamorelin quality before you inject it

Last updated 2026-07-24

Is there a real, FDA-approved version of tesamorelin?

Yes. Tesamorelin is FDA-approved under the brand names Egrifta and Egrifta SV, for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That approval rests on pooled phase 3 double-blind, placebo-controlled trials with safety extension data, not a single small study ^[1]. The drug itself is a synthetic analogue of growth hormone-releasing hormone (GHRH), stabilized against enzymatic breakdown so it has a longer half-life than native GHRH ^[2]. That's the important split to hold in your head. There is one approved product, made by one manufacturer, reviewed by FDA for a specific indication. There is also a much larger market of compounded tesamorelin and "research use" tesamorelin sold outside that system. Both can be labeled "tesamorelin." Only one of them has been through FDA's drug approval process. You can check any approved drug's status directly in Drugs@FDA, FDA's own database of approved products ^[3]. If your goal is to verify quality, the first question isn't "does this look pure." It's "which of these two systems is this vial coming from." That answer changes everything else you should check next.

What does the FDA approval actually cover, and what doesn't it cover?

The approval covers reduction of excess visceral abdominal fat in HIV patients with lipodystrophy. It does not cover general fat loss, anti-aging use, athletic performance, or GH support in people without HIV-associated lipodystrophy. Reviews describing the approved use are explicit that the pooled phase 3 data behind Egrifta was collected in HIV lipodystrophy patients specifically ^{[1] [4] [5]}. This matters for quality verification because it tells you what evidence exists to compare against. If a seller is marketing tesamorelin for general fat loss or muscle definition, they are, by definition, describing an off-label use, and the phase 3 safety and efficacy data doesn't automatically transfer to that population or that dose. A pharmacology review of the drug's development explicitly frames it within the lipodystrophy indication, not general metabolic enhancement ^[6]. So when you're checking quality, separate two different questions: is this the right molecule, made correctly (a chemistry question), and is this the right use for me (a medical question). A vial can pass the first check and still be a bad idea for a use that was never studied. Related: if you're pricing this out, see tesamorelin cost for what approved-brand versus compounded pricing actually looks like.

What's the difference between FDA-approved Egrifta and compounded tesamorelin?

Egrifta and Egrifta SV go through FDA's new drug approval pathway, with manufacturing facility inspections and batch-level quality control tied to that approval. Compounded tesamorelin is made by a 503A or 503B pharmacy under a different legal framework entirely, using bulk tesamorelin powder as a raw ingredient. Under federal law, pharmacy compounding is governed by 21 U.S.C. 353a, which sets conditions under which compounded drugs are exempt from full FDA approval requirements ^[7]. FDA maintains a specific list of bulk drug substances that 503A pharmacies are allowed to use, codified at 21 CFR 216.23 ^[8], and a separate bulks list for 503B outsourcing facilities at 21 CFR 216.24 [4 dup]. FDA also publishes and updates a nomination list of substances proposed for these lists, which you can check directly ^[9]. The practical difference: a compounded product can be legitimate, made in a properly registered 503A or 503B facility from an allowed bulk substance, tested for identity and potency. Or it can be made in an unregistered lab with no batch testing at all. From the outside, the vial looks the same either way. That's exactly why verification steps matter more for compounded tesamorelin than for the approved brand. | | FDA-approved (Egrifta/Egrifta SV) | Compounded (503A/503B) | Unregulated "research" vial |

How do I check if a tesamorelin source is a licensed pharmacy?

Ask directly which entity is compounding the product, whether it's a 503A compounding pharmacy or a 503B outsourcing facility, and whether it holds current state pharmacy board licensure. A real compounding pharmacy will tell you this without hesitation, usually with a facility name and state license number you can independently verify with that state's board of pharmacy. 503A pharmacies compound for individual patients with a valid prescription and are limited to the bulk substances FDA has placed on its 503A list under 21 CFR 216.23 ^[8]. 503B outsourcing facilities can compound in larger batches without a patient-specific prescription but are subject to more FDA oversight and their own bulks list under 21 CFR 216.24. If a seller can't or won't name their compounding facility, that's a hard stop, not a minor red flag. A second check: is a prescription and provider involved at all? Legitimate compounded tesamorelin requires a prescriber's order. If a site sells vials with no medical intake, no provider review, and ships to any address, you are almost certainly outside the pharmacy system entirely, in the "research chemical" market where none of the above protections apply.

What is a Certificate of Analysis, and should I ask for one?

Yes, always ask. A Certificate of Analysis (CoA) is a document from a testing lab confirming the specific batch you're receiving matches its labeled identity, purity, and concentration, usually via mass spectrometry and HPLC. For peptides broadly, quality problems including incorrect sequence, low purity, and degraded product have been documented enough that clinical reviews of injectable peptide therapy now flag independent verification as a real, practical concern for prescribers, more than a theoretical one [2 dup, ref below]. A primer for orthopaedic and sports medicine physicians on injectable peptide therapy specifically calls out the need for physicians to understand sourcing and quality verification before recommending any peptide product, precisely because manufacturing quality varies so widely across the unregulated peptide market ^[10]. A broader review of therapeutic peptides in orthopaedics likewise frames quality control and characterization as an active challenge for the field, not a solved problem ^[11]. What a real CoA should show: the specific peptide sequence tested (more than "tesamorelin"), a purity percentage typically expected above 98% for pharmaceutical-grade peptide, the testing method (HPLC and mass spec are standard), a batch or lot number matching what's on your vial, and a named, identifiable testing lab, more than a logo. If a seller offers a CoA that's undated, unattached to a lot number, or clearly copy-pasted across products, treat it as worthless. That's actually worse than no CoA, because it's designed to look like verification without providing any.

How can labs detect fake or substituted GHRH analogues?

Analytical chemists use liquid chromatography and mass spectrometry to confirm a peptide's exact molecular mass and sequence, which is how anti-doping and pharmaceutical labs catch substituted or degraded GHRH analogues. A 2021 review in Drug Testing and Analysis on detecting synthetic GHRH analogues describes the analytical methods used to identify these compounds and distinguish real analogues from substitutes or degradation products ^[12]. This is worth knowing even if you're not a chemist, because it tells you what "testing" should actually mean. A legitimate CoA is grounded in this kind of mass-based identity confirmation. A vague purity claim with no method named is not the same thing. If you want to go further than trusting a seller's paperwork, some independent third-party peptide testing services exist that will run your own sample and give you a report, at a cost, which is a reasonable step if you're buying compounded product in bulk or from a new source for the first time. The existence of rigorous detection methods also cuts the other way: it means degraded or incorrect product is chemically distinguishable from the real thing. Quality problems aren't invisible in principle. They're just invisible to you, standing there with a vial and no lab.

What should the correct tesamorelin dose and formulation look like?

The approved product, Egrifta, was studied in the phase 3 program and its safety extension at a subcutaneous injection regimen, with population pharmacokinetic modeling in both HIV-infected patients and healthy subjects published separately to characterize its absorption and clearance ^[13]. If a compounded product's suggested dosing looks wildly different from what's described in that pharmacokinetic literature, that's a reason to ask the prescribing provider to explain the reasoning, not necessarily a disqualifier on its own, since compounded formulations can differ in concentration. What you can check concretely: does the vial's labeled concentration match what your provider prescribed, does the reconstitution instruction make sense for that concentration, and is the injection technique consistent with subcutaneous administration as studied in the trials. If you need the practical how-to, see tesamorelin how to inject and tesamorelin injection sites for technique details that assume you already have a verified, correctly dosed product in hand. One more formulation note: Egrifta SV was reformulated from the original Egrifta specifically to improve reconstitution and reduce injection volume. If you're comparing a compounded product's stated volume and mixing process against the brand, know which version of the brand you're benchmarking against.

What side effects and safety signals should match the trial data?

The documented side effect profile from the phase 3 program includes injection site reactions, joint pain (arthralgia), swelling (edema), and effects on glucose metabolism, since tesamorelin raises IGF-1 and can affect insulin sensitivity ^{[1] [4]}. A meta-analysis of randomized controlled trials of tesamorelin in HIV-associated lipodystrophy reported on body composition, hepatic fat, metabolic, and safety outcomes across the pooled trial data, giving a more complete picture of expected effects and risks than any single trial . If you experience side effects that look nothing like this pattern, or side effects far more severe than what's described in the trial literature, that's a signal worth raising with your prescriber and worth documenting. It won't tell you definitively whether the product was substandard, but severe, unexpected reactions combined with an unverifiable source are the two red flags that should push you to stop and investigate rather than continue. Separately, IGF-1 monitoring is a standard part of legitimate tesamorelin prescribing, since it's the clinical marker used to confirm the drug is doing what it's supposed to do biologically. If a source sells you tesamorelin with no mention of monitoring at all, that's a gap in the medical process around the product, even if the product itself turns out to be fine.

Does tesamorelin quality differ for women, or for stacking with other peptides?

The phase 3 trials behind Egrifta's approval enrolled HIV patients with lipodystrophy; sex-specific efficacy and quality considerations for women using tesamorelin off-label are addressed in more detail at can women take tesamorelin peptide, and stacking considerations at tesamorelin peptide stack and best peptide to stack with tesamorelin. What's relevant here specifically to quality verification: stacking tesamorelin with other peptides multiplies your sourcing risk, because now you need every component in the stack independently verified, more than one. A review of injectable peptide therapy for sports medicine physicians notes that combination peptide use raises the stakes on quality control precisely because problems in one component can be hard to isolate from problems in another when side effects appear ^[10]. If you're stacking, verify each peptide's CoA separately. Don't accept a single combined "blend" CoA from a seller, since that format typically can't confirm the identity or purity of each individual peptide in the mix.

What are the real risks of buying unverified or 'research use only' tesamorelin?

Products labeled "research use only" or "not for human use" are explicitly outside any pharmacy licensing, FDA manufacturing oversight, or batch testing requirement, and a broader review of peptide therapies used off-label for musculoskeletal and athletic purposes describes the safety and efficacy evidence gap for exactly this category of unapproved product [1 (41966639)]. That label isn't a legal loophole for you as a buyer, it's an admission by the seller that no regulatory body has reviewed the product for human safety. The realistic risks: wrong peptide entirely, correct peptide but degraded or contaminated, correct peptide but wildly inaccurate concentration leading to under- or over-dosing, and bacterial contamination from non-sterile manufacturing. None of these are hypothetical concerns invented to scare you; they're the exact failure modes that CoA testing and licensed pharmacy oversight exist to catch. Buying research-labeled product and self-verifying with amateur testing is possible but genuinely hard to do reliably without lab equipment. The honest bottom line: if a source won't name a licensed compounding facility, won't provide a batch-specific CoA, and won't involve a prescriber, you're accepting all of that risk yourself with no real way to check it. That's a bad trade for a peptide that costs real money and that you're injecting.

What's the actual step-by-step checklist before you buy?

Run through this in order before any purchase: 1. Confirm whether you're buying the FDA-approved brand (Egrifta/Egrifta SV) or a compounded version. Check Drugs@FDA if you're unsure what's actually approved ^[3]. 2. If compounded, get the name of the specific 503A or 503B facility and verify its license with the relevant state board of pharmacy. 3. Confirm the substance is on FDA's applicable bulks list, 21 CFR 216.23 for 503A ^[8] or 21 CFR 216.24 for 503B. 4. Request a batch-specific Certificate of Analysis showing sequence identity, purity percentage, and testing method (HPLC/mass spec). 5. Confirm a licensed prescriber is reviewing your case, ordering appropriate labs (including IGF-1), and available for follow-up. 6. Compare the labeled concentration and reconstitution instructions against what your provider actually prescribed. 7. Watch for a side effect profile consistent with the published trial data (injection site reactions, arthralgia, edema, glucose effects) ^{[1] [4]} . 8. If stacking, verify each peptide independently, not as a combined blend. A provider-reviewed sourcing route, where a licensed prescriber and a named, accountable pharmacy partner handle the compounding and quality chain for you, removes most of the guesswork in steps 2 through 6. Tesamorelin Co's provider-reviewed pathway connects patients to that kind of pharmacy-verified route rather than leaving you to vet an anonymous online seller alone.

Frequently asked questions

Is compounded tesamorelin as good as FDA-approved Egrifta?

Compounded tesamorelin can be chemically identical if made correctly by a licensed 503A or 503B pharmacy from an allowed bulk substance ^[3]. But it hasn't gone through FDA's approval review as a finished product, so quality depends entirely on that specific pharmacy's practices. Ask for facility licensing and a batch-specific Certificate of Analysis before assuming equivalence.

How do I know if tesamorelin is FDA-approved or compounded?

Only Egrifta and Egrifta SV are FDA-approved brand products; you can confirm any drug's approval status in Drugs@FDA, FDA's official database ^[7]. Any product not sold under those brand names, including anything labeled generically as "tesamorelin" from a compounding pharmacy or research vendor, is not the FDA-approved version, even if it contains the same peptide.

What should a tesamorelin Certificate of Analysis include?

It should name the specific lot/batch, confirm peptide sequence and identity, state a purity percentage (typically 98%+ for pharmaceutical grade), name the testing method (HPLC and mass spectrometry are standard), and identify the testing lab. A generic, undated, or unattached CoA that isn't tied to your specific vial's batch number provides no real verification.

Can I test tesamorelin purity myself at home?

Not meaningfully. Confirming peptide identity and purity requires mass spectrometry and chromatography, the same analytical methods used in published detection research for GHRH analogues ^[6]. Third-party peptide testing labs exist and will test a submitted sample for a fee, which is a reasonable option for bulk or repeat purchases, but there's no reliable at-home test.

Is it legal to buy tesamorelin without a prescription?

No, legitimately. Tesamorelin, whether the approved brand or a compounded version, requires a prescription under the pharmacy compounding framework in 21 U.S.C. 353a ^[5]. Products sold without any prescriber involvement, often labeled "research use only," fall outside this legal framework entirely and carry no quality or safety oversight.

Why do some tesamorelin sellers say 'not for human use'?

That label is a legal disclaimer sellers use to avoid FDA drug regulation requirements, effectively admitting the product hasn't been reviewed for human safety or manufactured under pharmaceutical quality standards. Any product carrying this label that's being marketed for injection into people should be treated as unverified and unregulated, regardless of the vendor's other claims.

Does tesamorelin's FDA approval cover general fat loss or anti-aging use?

No. The approval covers reduction of excess visceral abdominal fat specifically in HIV-infected patients with lipodystrophy, based on pooled phase 3 trial data in that population ^{[1] [10]}. Use for general fat loss, bodybuilding, or anti-aging in people without HIV-associated lipodystrophy is off-label, meaning it falls outside the studied and approved use.

What side effects mean my tesamorelin might be low quality?

Severe, unexpected reactions well outside the documented profile, injection site reactions, arthralgia, edema, and glucose effects ^[1][15], especially combined with a source you can't verify, should prompt you to stop and contact your prescriber. This doesn't prove a quality problem on its own, but it's the pattern worth investigating rather than ignoring.

How is tesamorelin quality tested for anti-doping or forensic purposes?

Analytical labs use liquid chromatography and mass spectrometry to confirm exact molecular mass and sequence, distinguishing genuine GHRH analogues from substituted or degraded compounds, methods described in a 2021 review in Drug Testing and Analysis ^[6]. These are the same categories of testing a legitimate pharmaceutical Certificate of Analysis should be grounded in.

What's the difference between 503A and 503B compounding pharmacies?

503A pharmacies compound patient-specific prescriptions in smaller batches and are limited to substances on FDA's 503A bulks list under 21 CFR 216.23 ^[3]. 503B outsourcing facilities compound in larger batches without a patient-specific prescription, operate under more direct FDA oversight, and use a separate bulks list under 21 CFR 216.24. Both should hold current state pharmacy licensure.

Should I trust a peptide seller with lots of positive reviews but no CoA?

No. Reviews reflect user experience and marketing, not chemical identity or purity. A seller with strong reviews but no batch-specific Certificate of Analysis, no named compounding facility, and no prescriber involvement is still an unverified source. Quality verification has to be documentary and analytical, not reputational.

Does stacking tesamorelin with other peptides increase quality risk?

Yes, because it multiplies the number of components that need independent verification. A review of injectable peptide therapy for sports medicine physicians flags combination use as raising quality control stakes, since problems in one peptide can be hard to isolate from another if side effects occur ^[12]. Verify each peptide in a stack separately rather than accepting one combined blend CoA.

Sources

1. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis (PMID 20554713): FDA approval rests on pooled phase 3 double-blind placebo-controlled trials with safety extension data in HIV lipodystrophy patients
2. PubMed, Tesamorelin, Nature Reviews Drug Discovery (PMID 21283099): Tesamorelin is a synthetic GHRH analogue stabilized against enzymatic breakdown for a longer half-life
3. eCFR, 21 CFR 216.23, the 503A Bulks List: 503A compounding pharmacies are limited to bulk drug substances on FDA's specific 503A bulks list
4. eCFR, 21 CFR 216.24, the 503B Bulks List: 503B outsourcing facilities operate under a separate FDA bulks list distinct from the 503A list
5. Cornell Law, 21 U.S.C. 353a, pharmacy compounding: Pharmacy compounding is governed by federal statute setting conditions for exemption from full FDA drug approval requirements
6. PubMed, Advances in the detection of growth hormone releasing hormone synthetic analogs (PMID 34665524): Mass spectrometry and chromatography methods are used to detect and distinguish genuine GHRH analogues from substitutes
7. FDA, Drugs@FDA approved drug products database: Drugs@FDA is FDA's official database for confirming a drug's approval status
8. FDA, bulk drug substances nominated for use in compounding: FDA maintains and updates a nomination list of substances proposed for compounding bulks lists
9. PubMed, Population pharmacokinetic analysis of tesamorelin (PMID 25358450): Population pharmacokinetic modeling characterized tesamorelin absorption and clearance in HIV patients and healthy subjects
10. PubMed, Tesamorelin: a review of its use in HIV-associated lipodystrophy, Drugs (PMID 21668043): Documented side effect profile includes injection site reactions, arthralgia, edema, and glucose metabolism effects
11. PubMed, Therapeutic Peptides in Orthopaedics (PMID 41490200): Quality control and characterization remain active challenges in the therapeutic peptide field
12. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (PMID 41476424): Physicians need to understand sourcing and quality verification before recommending peptide products, and combination peptide use raises quality control stakes
13. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries (PMID 41966639): Unapproved, research-labeled peptide products carry a safety and efficacy evidence gap compared to approved drugs
14. PubMed, Body composition, hepatic fat, metabolic and safety outcomes of Tesamorelin: meta-analysis of RCTs (PMID 41545261): A meta-analysis of randomized controlled trials reported pooled body composition, hepatic fat, metabolic, and safety outcomes for tesamorelin